Abstract: The present disclosure relates to a container for retort food and, more specifically, to a container for retort food including: a container body in which food may be input and stored; and an inner cap covering the container body. The inner cap covering the container body has a predetermined depth, and thus, effective sterilization may be performed during a retort processing process, overflow of the food in the container body may be prevented, and there is an advantage in satisfying regulations regarding a packing space ratio.

Abstract: Disclosed in the present invention is a floating hologram system. The floating hologram system includes a diffuser configured to form a projection image using light beams transmitted from an image transmitter and diffuse the formed image, and a holographic optical element on which the image diffused from the diffuser is incident and which generates a virtual image floating at a position a predetermined distance therefrom and has a convex lens characteristic. A distance between the diffuser and the holographic optical element is determined based on a focal length of the holographic optical element and a distance from the holographic optical element to the virtual image.

Abstract: The present invention relates to a pharmaceutical composition for preventing or treating a muscular disease or cachexia, comprising, as an active ingredient, a miRNA located in Dlk1-Dio3 cluster or a variant thereof. In the present invention, it has been found that expression of miRNAs located in the Dlk1-Dio3 cluster is decreased as age increases. In particular, in a case where most of the miRNAs are over-expressed in fully differentiated myotubes, it has been confirmed that the diameter of the myotubes increases. In addition, also in a tumor-induced cachexia mouse model, it has been confirmed that cachexia was improved by inhibiting Atrogin-1 protein. Accordingly, the miRNA located in the Dlk1-Dio3 cluster or a variant thereof can be usefully utilized for the treatment and prevention of an Atrogin-1-dependent muscular disease and cachexia.

Abstract: The present invention provides a swing-type experience apparatus including: two vertical columns (110) configured to be vertically installed into the ground; a driving device (120) configured to be provided on the upper end of any one of the two vertical columns; a rotating shaft (130) configured to be provided on the upper ends of the two vertical columns in a lateral direction and to be rotated by the driving device; two vertical bars (150) configured such that one end of each thereof is fastened to the rotating shaft and the other end of each thereof is connected to a horizontal bar (140); wherein the driving device includes a motor (121) and a clutch (125) configured to selectively transmit the rotating force of the motor and then transfer the rotating force to the rotating shaft (130).

Abstract: The present invention relates to sobrerol or a pharmaceutically acceptable salt thereof, which can promote differentiation of myoblasts to form myotubes, thereby preventing muscle weakness and effectively improving muscle functions. Therefore, the pharmaceutical composition containing the same can be effectively used for preventing or treating muscle weakness related diseases.

Abstract: The present invention provides a swing-type experience apparatus including: two vertical columns (110) configured to be vertically installed into the ground; a driving device (120) configured to be provided on the upper end of any one of the two vertical columns; a rotating shaft (130) configured to be provided on the upper ends of the two vertical columns in a lateral direction and to be rotated by the driving device; two vertical bars (150) configured such that one end of each thereof is fastened to the rotating shaft and the other end of each thereof is connected to a horizontal bar (140); wherein the driving device includes a motor (121) and a clutch (125) configured to selectively transmit the rotating force of the motor and then transfer the rotating force to the rotating shaft (130).

Abstract: The present invention relates to a composition and a kit for diagnosis of muscle weakness-related disease, which comprises agents for measuring the expression levels of gelsolin and tetranectin, and to a method of diagnosing muscle weakness-related disease by using the same. The composition, kit and method for diagnosis of muscle weakness-related disease according to the present invention make it possible to diagnose muscle weakness-related disease in an easy and rapid manner by molecular diagnosis, thereby systemically managing the muscle weakness-related disease while increasing therapeutic efficacy against the muscle weakness-related disease.

Abstract: The present invention relates to sobrerol or a pharmaceutically acceptable salt thereof, which can promote differentiation of myoblasts to form myotubes, thereby preventing muscle weakness and effectively improving muscle functions. Therefore, the pharmaceutical composition containing the same can be effectively used for preventing or treating muscle weakness related diseases.

Abstract: The present invention relates to A method for promoting the differentiation of myoblasts comprising treating myoblasts with butylpyridinium, a derivative thereof, or a pharmaceutically acceptable salt thereof; a method for strengthening muscles comprising administering butylpyridinium, a derivative thereof, or a pharmaceutically acceptable salt thereof to a subject in need thereof; a feed or feed additive for strengthening muscles comprising butylpyridinium, a derivative thereof, or a pharmaceutically acceptable salt thereof; a method for treating a disease associated with muscle weakness comprising administering butylpyridinium, a derivative thereof, or a pharmaceutically acceptable salt thereof to a subject in need thereof.

Abstract: An apparatus includes a first predistorter configured to calculate a first predistortion parameter and configured to distort an input signal using the first predistortion parameter to output a first distortion signal, a second predistorter configured to calculate a second predistortion parameter and configured to distort the first distortion signal using the second predistortion parameter to output a second distortion signal, a power supply configured to receive the first distortion signal to generate a first envelope signal, and configured to limit a bandwidth of the first envelope signal to obtain a second envelope signal to supply a source voltage, and a power amplifier configured to receive the source voltage and to output an output signal obtained by amplifying the second distortion signal.

Abstract: A method and an apparatus for determining validity of samples for a digital pre-distortion apparatus is disclosed. It is an object of at least one embodiment to provide a method and an apparatus for determining validity of samples for a digital pre-distortion apparatus that is configured to compensate for nonlinearity of a power amplifier in an efficient manner by accurately estimating a pre-distortion coefficient with a low-capacity memory.

Abstract: An apparatus includes a first predistorter configured to calculate a first predistortion parameter and configured to distort an input signal using the first predistortion parameter to output a first distortion signal, a second predistorter configured to calculate a second predistortion parameter and configured to distort the first distortion signal using the second predistortion parameter to output a second distortion signal, a power supply configured to receive the first distortion signal to generate a first envelope signal, and configured to limit a bandwidth of the first envelope signal to obtain a second envelope signal to supply a source voltage, and a power amplifier configured to receive the source voltage and to output an output signal obtained by amplifying the second distortion signal.

Abstract: The present invention relates to A method for promoting the differentiation of myoblasts comprising treating myoblasts with butylpyridinium, a derivative thereof, or a pharmaceutically acceptable salt thereof; a method for strengthening muscles comprising administering butylpyridinium, a derivative thereof, or a pharmaceutically acceptable salt thereof to a subject in need thereof; a feed or feed additive for strengthening muscles comprising butylpyridinium, a derivative thereof, or a pharmaceutically acceptable salt thereof; a method for treating a disease associated with muscle weakness comprising administering butylpyridinium, a derivative thereof, or a pharmaceutically acceptable salt thereof to a subject in need thereof.

Abstract: The present invention relates to an anticancer agent containing a TMPRSS4 (transmembrane protease, serine 4) inhibitor as an effective ingredient, more precisely an anticancer agent containing an inhibitor of TMPRSS4 activity as an effective ingredient. The anticancer agent of the present invention can be used effectively for the treatment of cancer by inhibiting TMPRSS4 expression in cancer cells and thereby inhibiting cancer cell invasion and cancer cell growth.

Abstract: The present invention relates to an anticancer agent containing a TMPRSS4 (transmembrane protease, serine 4) inhibitor as an effective ingredient, more precisely an anticancer agent containing an inhibitor of TMPRSS4 activity as an effective ingredient. The anticancer agent of the present invention can be used effectively for the treatment of cancer by inhibiting TMPRSS4 expression in cancer cells and thereby inhibiting cancer cell invasion and cancer cell growth.

Abstract: Mechanisms regulating cell proliferation stop and differentiation initiation during the development stage of mammalian embryo, and the proteins involved therein, are presented. Differentiation regulators, methods of regulating differentiation, transgenic organisms with loss of expression of the differentiation regulator, and methods of preparing the transgenic organisms, are provided.

Abstract: Mechanisms regulating cell proliferation stop and differentiation initiation during the development stage of mammalian embryo, and the proteins involved therein, are presented. Differentiation regulators, methods of regulating differentiation, transgenic organisms with loss of expression of the differentiation regulator, and methods of preparing the transgenic organisms, are provided.

Abstract: A method for forming a dual-gate for a semiconductor device includes an N-counter implantation process that implants an N-type impurity ion like phosphorous through an ultra low energy implanter to provide an in-situ boron doped polysilicon layer with a stable characteristic.